Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

Implied Volatility Surging for Clovis (CLVS) Stock Options

Clovis Oncology benefited from a lot of good news last month.

This Pharma Stock Soared More Than 360% in November

Clovis Oncology: Best In Class

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock?

Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue?

The stock price is soaring. Are investors getting ahead of themselves by speculating on a potential acquisition?

Is Clovis Oncology Really a Buyout Candidate?

Exelixis

Sorrento Therapeutics Inc

These three names could soar early in 2020.

3 Top Growth Stocks to Buy in December

Riding robust fundamental improvements, Clovis Oncology is enjoying a 145.6% gain in the past 20-days.

Clovis: Second Wave To Catapult Shares Higher

As of late, it has definitely been a great time to be an investor in Clovis Oncology, Inc. (CLVS).

Clovis Oncology, Inc. (CLVS) Shares March Higher, Can It Continue?

Clovis (CLVS) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Clovis (CLVS) Looks Good: Stock Adds 6.3% in Session

Arrowhead Pharmaceuticals

Dicerna Pharmaceuticals

Medicines

A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?

The Return of M&A Activity Is Lifting These Biotech Stocks Today

 Luckin Coffee

Luna Innovations

Here are three stocks with continued technical momentum in the days and weeks after strong earnings releases.

3 Momentum Stocks To Watch Post-Earnings

Sarepta Therapeutics

These dirt cheap healthcare stocks could be poised for a major upswing in 2020.

These 3 Value Stocks - Are Absurdly Cheap Right Now.

Clovis: Market Valuation Is Still Far From Intrinsic Value

Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.

Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q3 2019 Results - Earnings Call Transcript

Clovis (CLVS) delivered earnings and revenue surprises of 1.56% and 3.56%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q3 Loss, Tops Revenue Estimates

Clovis Oncology: A Classic Story Of Value Disconnect

Clovis (CLVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Clovis Oncology (CLVS) to Report a Decline in Earnings: What to Look Out for

Clovis Oncology continues to disappoint shareholders who are hoping for a potential buyout. Recently, the company announced a licensing agreement with 3B Pharmaceuticals to expand the pipeline.

Clovis Oncology: Debating On Doubling Down Or Ditching

Agenus

Puma Biotechnology

These three beaten-down cancer stocks could prove to be amazing value plays.

3 Cancer Treatment Stocks - to Buy Right Now

Goldman Sachs lowers price target for Clovis' (CLVS) shares taking into account the risk of lower future revenues due to rising competition in the PARP inhibitor segment.

Clovis (CLVS) Shares Drop on Goldman Sachs' Bearish Outlook

Wall Street is questioning the value and purpose of a recent deal.

Here's Why Clovis Oncology Fell as Much as 13.5% Today

Clovis (CLVS) enters into licensing and collaboration agreement with 3B Pharmaceuticals and acquires rights to FAP targeted radiopharmaceutical therapy for developing new cancer treatments.

Clovis Gains Rights to Pre-Clinical Cancer Program for $12M

Investors need ongoing clinical trials to deliver -- and for the business to rein in expenses.

News for Clovis Oncology Stock (CLVS)